Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis

被引:0
作者
Yang Jiao
Yan Lu
Xiao-ying Li
机构
[1] Shanghai Institute of Endocrinology and Metabolism,Department of Endocrine and Metabolic Diseases
[2] Shanghai Clinical Center for Endocrine and Metabolic Diseases,The Key Laboratory of Endocrine Tumors and the Division of Endocrine and Metabolic Diseases
[3] Ruijin Hospital,undefined
[4] Shanghai Jiao Tong University School of Medicine,undefined
[5] E-Institute of Shanghai Universities,undefined
来源
Acta Pharmacologica Sinica | 2015年 / 36卷
关键词
farnesoid X receptor; non-alcoholic fatty liver disease; liver; triglyceride metabolism; glucose metabolism; drug discovery;
D O I
暂无
中图分类号
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) is characterized by the aberrant accumulation of triglycerides in hepatocytes in the absence of significant alcohol consumption, viral infection or other specific causes of liver disease. NAFLD has become a burgeoning health problem both worldwide and in China, but its pathogenesis remains poorly understood. Farnesoid X receptor (FXR), a member of the nuclear receptor (NR) superfamily, has been demonstrated to be the primary sensor for endogenous bile acids, and play a crucial role in hepatic triglyceride homeostasis. Deciphering the synergistic contributions of FXR to triglyceride metabolism is critical for discovering therapeutic agents in the treatment of NAFLD and hypertriglyceridemia.
引用
收藏
页码:44 / 50
页数:6
相关论文
共 50 条
  • [21] Antiatherosclerotic effect of farnesoid X receptor
    Mencarelli, Andrea
    Renga, Barbara
    Distrutti, Eleonora
    Fiorucci, Stefano
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2009, 296 (02): : H272 - H281
  • [22] Role of farnesoid X receptor in cholestasis
    Yuan, Zhi Qing
    Li, Ke Wei
    JOURNAL OF DIGESTIVE DISEASES, 2016, 17 (08) : 501 - 509
  • [23] Structural basis of the farnesoid X receptor/retinoid X receptor heterodimer on inverted repeat DNA
    Jiang, Longying
    Liu, Xueke
    Liang, Xujun
    Dai, Shuyan
    Wei, Hudie
    Guo, Ming
    Chen, Zhuchu
    Xiao, Desheng
    Chen, Yongheng
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2023, 21 : 3149 - 3157
  • [24] Characterizing ligands for farnesoid X receptor - available in vitro test systems for farnesoid X receptor modulator development
    Merk, Daniel
    Steinhilber, Dieter
    Schubert-Zsilavecz, Manfred
    EXPERT OPINION ON DRUG DISCOVERY, 2014, 9 (01) : 27 - 37
  • [25] Farnesoid X receptor agonist decreases lipid accumulation by promoting hepatic fatty acid oxidation in db/db mice
    Liu, Yujie
    Song, An
    Yang, Xi
    Zhen, Yunfeng
    Chen, Weiwei
    Yang, Linquan
    Wang, Chao
    Ma, Huijuan
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2018, 42 (03) : 1723 - 1731
  • [26] The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis
    Xiang, Dong
    Yang, Jinyu
    Liu, Lu
    Yu, Hengyi
    Gong, Xuepeng
    Liu, Dong
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 168
  • [27] The pathophysiological function of non-gastrointestinal farnesoid X receptor
    Yan, Nana
    Yan, Tingting
    Xia, Yangliu
    Hao, Haiping
    Wang, Guangji
    Gonzalez, Frank J.
    PHARMACOLOGY & THERAPEUTICS, 2021, 226
  • [28] Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis
    Venetsanaki, Vasiliki
    Karabouta, Zacharoula
    Polyzos, Stergios A.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 863
  • [29] Bacterial metabolites directly modulate farnesoid X receptor activity
    Zhang, Xianqin
    Osaka, Toshifumi
    Tsuneda, Satoshi
    NUTRITION & METABOLISM, 2015, 12
  • [30] Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice
    Xiang, Minqi
    Qian, Xu
    Han, Luyu
    Wang, Hui
    Wang, Jiqiu
    Liu, Weiren
    Gu, Yanyun
    Yao, Shuangshuang
    Yang, Jian
    Zhang, Yifei
    Peng, Ying
    Zhang, Zhiguo
    ISCIENCE, 2023, 26 (04)